Metraipolis › archive › dc_daa71cab7408

Advantage of Scheduled Upfront Lenvatinib Administration Followed by Transarterial Chemoembolization Therapy Over Lenvatinib Monotherapy in Patients With… — Europe PMC PMID:41546425

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41546425
DOI
10.1002/cam4.71503
License (as archived)
solo-consultazione
Archived
2026-11-07T06:20:16.708Z
SHA-256 of the archived text
f0c047afc80684bd64216cbd4d2648ce4a6ca62d4be408cbf186e3d8f9f081ea
Stable URL of this page
https://metraipolis.com/documento/dc_daa71cab7408

How to cite

Advantage of Scheduled Upfront Lenvatinib Administration Followed by Transarterial Chemoembolization Therapy Over Lenvatinib Monotherapy in Patients With… — Europe PMC PMID:41546425 — Europe PMC (en), https://europepmc.org/article/MED/41546425 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_daa71cab7408 (Metraipolis archive dc_daa71cab7408, sha256 f0c047afc80684bd64216cbd4d2648ce4a6ca62d4be408cbf186e3d8f9f081ea)
BibTeX
@misc{dcdaa71cab7408,
  title = {Advantage of Scheduled Upfront Lenvatinib Administration Followed by Transarterial Chemoembolization Therapy Over Lenvatinib Monotherapy in Patients With… — Europe PMC PMID:41546425},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41546425},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_daa71cab7408; sha256 f0c047afc80684bd64216cbd4d2648ce4a6ca62d4be408cbf186e3d8f9f081ea},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41546425. Agents can read the archived copy with the MCP tool read_document.